Photocure $PHO setting up for IHS?An average Q3 report for Photocure today giving some selling action, painting up the framework for a nice inverted head & shoulders formation within the long uptrend of the stock.
0.0NOK
267.00 KNOK
500.66 MNOK
26.22 M
About PHOTOCURE ASA
Sector
Industry
CEO
Daniel Schneider
Website
Headquarters
Oslo
Founded
1993
ISIN
NO0010000045
FIGI
BBG003FWM0C8
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. Its products include Metvix for nonmelanoma skin cancer, Hexvix/Cysview for better detection and management of bladder cancer, and Cevira which is a photodynamic drug-device combination product for non-surgical treatment of high-grade cervical dysplasia. The company operates through the Commercial Franchise and Development Portfolio segments. The Commercial Franchise segment includes the sale of Hexvix/Cysview in the U.S. and Europe and other sales from partners and other products. The Development Portfolio segment focuses on the development of pipeline products. The company was founded in 1997 and is headquartered in Oslo, Norway.
Photocure $PHO well that escalated quicklyPhotocure breaking free upwards from important 100 NOK resistance and heads for analyst BUY recommendations at 130+
Photocure $PHO Partners with Asieris on Hexvix in ChinaPhotocure Partners with Asieris MediTech to Commercialize Hexvix in Mainland China and Taiwan
Agreement Expands Photocure’s Hexvix®/Cysview® Franchise Footprint to over 30 Countries
Oslo, Norway January 26, 2021, Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformati
Photocure $PHO close at 100 NOK at all time high market cap100 NOK the last major resistance in the chart.
Ready to break out from Triangle formation.
Nice EMA 20 / 100 Bounce
Strong Analyst BUY consensus from DNB Markets, ABG, Norne etc.
PHOTOCURE buying opportunitySo I can be quick on Photocure.
We are in a nice long uptrend, which is currently hitting resistance, forming an ascending triangle.
The only sure strategy here is to wait for a break and retest of this triangle.
Analyst increase Photocure $PHO price target to 130 (125) ABG Sundal Collier: Photocure - Q3: a solid stepping stone towards expansion
Q3 results due 10 November US recovery and EU commercialisation in the spotlight Tweaking near term ests. – DCF TP up to NOK 130 (125)
Photocure Self Explanatory.
Target flexible (Calculated Wave 1 = Wave 5). Prioritize channel resistance.
Photocure Long (retracement first)The whole stock market is experiencing the same type of "crack" as it did back in Feb/March, now being fueled by a Covid second wave and uncertainty around the US elections. Photocure's RSI is approaching its year low levels in March. The down period in March lasted for about 1 month. The length of
Photocure $PHO test breakout from ascending triangle formationLook for increased trading volume confirming breakout above NOK 94
Photocure $PHO trading above previous top as shorts reduce posThe Photocure share price has been increasing steadily even in the face of short sellers thas has been adding to their positions in Photocure stock for three weeks straight.
With the stock now trading above the last top, longs will be hoping to see a short squeeze effect in the the price developmen
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PHOO is 57.8 NOK — it has decreased by 8.54% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange PHOTOCURE ASA stocks are traded under the ticker PHOO.
PHOTOCURE ASA is going to release the next earnings report on May 15, 2024. Keep track of upcoming events with our Earnings Calendar.
PHOO stock is 9.34% volatile and has beta coefficient of 0.63. Check out the list of the most volatile stocks — is PHOTOCURE ASA there?
One year price forecast for PHOTOCURE ASA has a max estimate of 87.0 NOK and a min estimate of 85.0 NOK.
PHOO earnings for the last quarter are −0.18 NOK per share, whereas the estimation was −0.43 NOK resulting in a 58.77% surprise. The estimated earnings for the next quarter are −0.11 NOK per share. See more details about PHOTOCURE ASA earnings.
PHOTOCURE ASA revenue for the last quarter amounts to 107.50 M NOK despite the estimated figure of 111.46 M NOK. In the next quarter revenue is expected to reach 127.58 M NOK.
Yes, you can track PHOTOCURE ASA financials in yearly and quarterly reports right on TradingView.
PHOO net income for the last quarter is 12.48 M NOK, while the quarter before that showed −4.79 M NOK of net income which accounts for 360.57% change. Track more PHOTOCURE ASA financial stats to get the full picture.
Today PHOTOCURE ASA has the market capitalization of 1.46 B, it has decreased by 7.26% over the last week.
No, PHOO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PHOO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PHOTOCURE ASA stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PHOTOCURE ASA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PHOTOCURE ASA stock shows the sell signal. See more of PHOTOCURE ASA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on PHOTOCURE ASA future price: according to them, PHOO price has a max estimate of 87.00 NOK and a min estimate of 85.00 NOK. Read a more detailed PHOTOCURE ASA forecast: see what analysts think of PHOTOCURE ASA and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PHOTOCURE ASA EBITDA is 152.58 M NOK, and current EBITDA margin is 30.48%. See more stats in PHOTOCURE ASA financial statements.